Vivelle-Dot
Vivelle-Dot is the best-known twice-a-week patch. Sandoz holds its approval and also sells it unbranded. Mylan, Zydus and Amneal (as Dotti) make generics the FDA rates against it.
ASHP doesn't mention Vivelle-Dot or Sandoz's unbranded version either way. Among its generics, Dotti 0.0375 and 0.1 mg are on back order with no date, Zydus's three highest strengths are on allocation, and Mylan's version is listed as available apart from 0.05 mg.
- Made by
- Sandoz
- Changed
- Twice a week
- Strengths
- 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, 0.1 mg
- FDA approval
- NDA 020538
- Medfinder in-stock rate
- 2% of 456 checks
Status, with the patches rated against it
| Patch | 0.025 mg | 0.0375 mg | 0.05 mg | 0.075 mg | 0.1 mg |
|---|---|---|---|---|---|
| Vivelle-DotSandoz · twice a week | No data | No data | No data | No data | No data |
| Sandoz twice-weeklySandoz · twice a week | No data | No data | No data | No data | No data |
| Mylan twice-weekly (VD)Mylan (Viatris) · twice a week | Available | Available | Limited | Available | Available |
| Zydus twice-weeklyZydus · twice a week | No data | No data | Limited | Limited | Limited |
| DottiAmneal · twice a week | Available | Short | Available | Available | Short |
- Available
- Limited
- Short
- Discontinued
- No data
Statuses checked October 18, 2026 against each row's source. We re-check every week.
Each strength in detail
0.025 mg (no data) · 0.0375 mg (no data) · 0.05 mg (no data) · 0.075 mg (no data) · 0.1 mg (no data)
Any change of brand, strength or form is a decision for your prescriber, and your pharmacist can check what they can order.
Get one email when your strength is back
Pick the strength on your box. When ASHP, the makers or Drug Shortages Canada list it as back in normal supply, we write once with what changed.
Sources
- Vivelle-Dot label, DailyMed, Sandoz, November 17, 2023.
- Estradiol transdermal system (authorized generic of Vivelle-Dot) label, DailyMed, Sandoz, January 30, 2025.
- Estradiol transdermal system, twice weekly (ANDA 201675) label, DailyMed, Mylan, June 17, 2025.
- Estradiol transdermal system, twice weekly (ANDA 206241) label, DailyMed, Zydus, March 15, 2024.
- Dotti label, DailyMed, Amneal, May 14, 2024.
- Drug Shortage Detail: Estradiol Transdermal System, ASHP, August 12, 2026.
- Estradiol shortage tracker, Medfinder, October 18, 2026.
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (data files), FDA, October 9, 2026.